About the Event
With a focus on rapidly advancing a novel solid tumor targeting and penetration technology to improve the efficacy of anticancer drugs, Lisata has:
- A seasoned management with a track record of more than two dozen successful product launches, including major oncology products
- A platform technology with multiple clinical stage programs underway
- A wealth of significant milestones over the next 24 months
- Fast Track and Orphan Drug Designations granted by the U.S. FDA in pancreatic ductal adenocarcinoma (PDAC)
Watch this webinar with Lisata’s President and CEO, David J. Mazzo, PhD, to hear how their platform technology uniquely addresses the two challenges that plague the successful treatment of solid tumors, specifically and selectively targeting the tumor and, more importantly, facilitating the penetration of drugs through the harsh protective coating these tumors produce.